UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000049667
Receipt number R000056569
Scientific Title Study of the superiority of Complete Nutrition Meals in hypertensive patients.
Date of disclosure of the study information 2022/12/07
Last modified on 2023/03/27 13:02:17

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study of the superiority of Complete Nutrition Meals in hypertensive patients.

Acronym

Study of the superiority of Complete Nutrition Meals in hypertensive patients.

Scientific Title

Study of the superiority of Complete Nutrition Meals in hypertensive patients.

Scientific Title:Acronym

Study of the superiority of Complete Nutrition Meals in hypertensive patients.

Region

Japan


Condition

Condition

Essential Hypertension

Classification by specialty

Medicine in general

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Verification of the superiority of eating Complete Nutrition Meals in hypertensive patients.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Clinic blood pressure

Evaluate before ingestion, 6 weeks, 12 weeks, 18 weeks and 24 weeks after ingestion.

Key secondary outcomes

Therapeutic intensity score
Drug change score
Number of drug types
Home blood pressure (morning, night)
Physical measurement (body weight, BMI, abdominal circumference)
Body-fat percentage
QOL examination
Physical activity
Meal record (BDHQ)
Fasting clinical examination

Evaluate before ingestion, 6 weeks, 12 weeks, 18 weeks and 24 weeks after ingestion.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Research food replaces one meal daily with Complete Nutrition Meals for 24 weeks.

Interventions/Control_2

None

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

50 years-old <=

Age-upper limit

75 years-old >

Gender

Male and Female

Key inclusion criteria

(1) Male and female who were diagnosed with essential hypertension more than one year ago and are 50 or more and under 75 years of age.
(2) Subjects who have been receiving the same hypertension treatment for 3 months or more before the pre-examination.
(3) Subjects with systolic blood pressure of 140 mmHg or more and less than 180 mmHg for 3 months before the pre-examination.
(4) Subjects who had systolic blood pressure of 140 mmHg or more and less than 180 mmHg more than a months before the pre-examination.
(5) Subjects with systolic blood pressure of 140 mmHg or more and less than 180 mmHg at the time of pre-examination.
(6) Subjects with a BMI of 23 kg/m 2 or more.
(7) Subjects who have agreed in writing to participate in the study and can be tested on the designated test date.

Key exclusion criteria

(1) Subjects who cannot continuously ingest research foods due to business trips etc. during the intake period.
(2) Subjects with concomitant diabetes mellitus.
(3) Subjects with severe hepatic impairment (4) subjects with renal impairment.
(5) Subjects who self-reported a weight change of 5% or more within 3 months before the pre-examination.
(6) Subjects with a history of myocardial infarction or stroke within the past year.
(7) Subjects who are planning to change, add new or discontinue the treatment method for hypertension between the pre-examination and the intake start examination.
(8) Subjects with food allergies.
(9) Subjects with an average daily alcohol intake of more than 60 g.
(10) Subjects with a smoking habit of more than 21 cigarettes per day.
(11) Subjects who are judged by the principal investigator to be at risk of being hospitalized or having dietary restrictions etc. that may affect the continuation of the study or the intake of the research foods.
(12) Subjects with diseases that may turn into serious adverse events during the study period, such as cancer.
(13) Subjects who cannot properly store and ingest research foods due to reasons such as the inability to install a freezer to distribute and the lack of a microwave oven.
(14) Subjects who cannot record diary or answer questionnaires on the Web.
(15) Subjects with implantable medical devices such as cardiac pacemakers or life-sustaining medical devices such as biometric monitors.
(16) Subjects who are planning to become pregnant or breastfeed during the study period.
(17) Subjects who are participating in other clinical studies (including clinical trials) at the start of this study.

Target sample size

400


Research contact person

Name of lead principal investigator

1st name Futoshi
Middle name
Last name Nakamura

Organization

NISSIN FOODS HOLDINGS CO., LTD.

Division name

Future Food Research & Development Division

Zip code

192-0001

Address

2100 Tobukimachi, Hachioji-shi, Tokyo

TEL

042-696-7606

Email

futoshi.nakamura@nissin.com


Public contact

Name of contact person

1st name Shingo
Middle name
Last name Yamamichi

Organization

EP Mediate Co., Ltd.

Division name

Foods Department, Trial Planning Section

Zip code

162-0821

Address

1-8 Tsukudocho, Shinjuku-ku, Tokyo Kagurazaka AK Building 7F

TEL

090-4821-1099

Homepage URL


Email

yamamichi.shingo578@eps.co.jp


Sponsor or person

Institute

EP Mediate Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

NISSIN FOOD PRODUCTS CO., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Shintokai Yokohama Minoru Clinic Institutional Review Board

Address

1-13-8, Bessho, Minami-ku, Yokohama-city, Kanagawa

Tel

042-648-5551

Email

yminoru-irb@eps.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 12 Month 07 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2022 Year 06 Month 30 Day

Date of IRB

2022 Year 06 Month 30 Day

Anticipated trial start date

2022 Year 12 Month 08 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2022 Year 12 Month 02 Day

Last modified on

2023 Year 03 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000056569


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name